Close Menu

NEW YORK – UK cancer diagnostics and therapies developer Theragnostics today said that it has licensed intellectual property from AstraZeneca covering the use of certain selected radionuclide-labelled Poly (ADP-Ribose) Polymerase inhibitors in the diagnostics field globally.

In addition, Theragnostics has an option to exclusively license the IP for therapeutic uses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
18
Sponsored by
Mission Bio

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Dec
02

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.